A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

Trial number:
NCT05337137
Trial phase:
1, 2
Study type:
Immunotherapy, Targeted therapy
Overall status:
Recruiting

Study start date

May, 2022

Scientific title

A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma

Summary

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).

Histologically confirmed advanced/metastatic hepatocellular carcinoma (HCC)Naïve to systemic therapy for advanced/metastatic HCC (prior neo-adjuvant or adjuvant immunotherapy is permitted if recurrence occurs ≥ 6 months after treatment completion and the case is discussed with BMS medical team) Child-Pugh score of 5 or 6 (ie, Child-Pugh A) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Study design

Primary purpose: Treatment, Allocation: Randomized, Intervention model: Parallel Assignment, Masking: Triple, Subject masked: Yes, Caregiver masked: Yes, Investigator masked: Yes,

Conditions

Carcinoma, Hepatocellular

Other study ID numbers

CA224-106; 2021-003606-53; U1111-1267-1579

Choose trial site (105)